Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with TACE followed by sintilimab + bevacizumab for unresectable hepatocellular carcinoma
ChiCTR2500102228Phase 2Recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Objective response rate. Started May 2025; status: recruiting.
02
Drugs
cadonilimabsintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500102228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102228.